newsPradaxa® (dabigatran etexilate) receives final NICE recommendation for stroke prevention in atrial fibrillation in the UK19 March 2012 | By NICEPradaxa® must now be made available for use by the UK National Health Service (NHS)...
newsBayer’s Xarelto® approved in the EU for the prevention of stroke in patients20 December 2011 | By Bayer HealthCareThe only new oral anticoagulant approved in three indications across all 27 EU member states...
newsNew data presented on Phase 3 trial of ELIQUIS® (apixaban)13 November 2011 | By PfizerBristol-Myers Squibb Company and Pfizer Inc. announced the results of the Phase 3 ADOPT trial...
newsBoehringer Ingelheim implements additional guidance supporting appropriate use of Pradaxa® (dabigatran etexilate) in Europe27 October 2011 | By Boehringer IngelheimUpdate across Europe on Pradaxa®...
newsRadiometer’s AQT90 FLEX aids point of care D-dimer testing at Frimley Park11 October 2011 | By kdm communications limitedFrimley Park Hospital in Surrey, UK, has recently invested in Radiometer’s AQT90 FLEX system...
newsELIQUIS® (apixaban) approved in Europe for preventing venous thromboembolism20 May 2011 | By Bristol-Myers Squibb CompanyThe European Commission has approved ELIQUIS® in the 27 countries of the EU...
newsApixaban statistically superior to aspirin in reducing the composite of stroke or systemic embolism10 February 2011 | By PfizerBristol-Myers Squibb Company and Pfizer Inc. announce the publication of their AVERROES study of apixaban in The New England Journal of Medicine...
newsAPPRAISE-2 Study with Investigational Compound Apixaban in Acute Coronary Syndrome Discontinued18 November 2010 | By BUSINESS WIRECompanies have discontinued the Phase 3 APPRAISE-2 clinical trial in patients...
